Compounds · Other compounds · continued

Why catalogue breadth is not evidence of anything — what changed since posts 61–67

Compounds › Other compounds custom synthesis mislabelling needs a source research use only

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.

OkaforTL3Regular2 Oct 2025#61

Thank you for the correction. I would rather find out here than later.

1 like 10mo

il.dumitruTL23 Oct 2025 · edited#62

On post #58 — agreed on the reasoning, with one qualification.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

The general answer and the answer for your case may diverge here.

6 likes 10mo

g.haalandTL3Regular4 Oct 2025#63

h.varga, post #52: This subcategory exists because some people will research compounds outside the main groups discussed here. The standard of evidence and honesty about its limits applies to everything discussed, not just to approved drugs. That is what the documentation says. What happens in practice is usually close. Go to post

PT-141 was developed from the same family with a different receptor profile, and it has a considerably better documented human evidence base than most compounds discussed in this subcategory.

17 likes in reply to #52 10mo

e.coelhoTL25 Oct 2025#64

This subcategory exists because some people will research compounds outside the main groups discussed here. The standard of evidence and honesty about its limits applies to everything discussed, not just to approved drugs.

32 likes 10mo

f.abrahamsenTL2Member7 Oct 2025#65

Where the catalogue breadth discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the same sentence with different clothes on.

3 likes 10mo

ca.haddadTL28 Oct 2025#66

Why catalogue breadth is not evidence of anything: a supplier listing 500 compounds does not make the 450 untested ones likely to work. It makes them untested compounds with supplier pages.

I have said this before in a thread nobody could find, so it is worth repeating.

10 likes 10mo

GDashwoodTL3Regular9 Oct 2025#67

h.lindqvist, post #49: Narrowing post #46, because the general version has more than one answer. Two things can be true about catalogue breadth at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the argument here is people defending the first against attacks on the second. Go to post

Post #64 is right about the mechanism and I think understates the practical bit.

A compound with no established assay is a compound where a certificate can say almost anything. That is not an accusation about anyone; it is a statement about what a document can carry.

Old habit: I write down the expected answer before I calculate it.

23 likes in reply to #49 10mo

Suggested topics

Topic	Participants	Replies	Views	Activity
Compounds this community declines to help with, and why — does this still hold? Compounds › Other compounds custom synthesis research use only mislabelling Compounds this community declines to help with, and why — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first post,…	+3	7	26k	7h
Sequence verification for an obscure compound: how it is done Compounds › Other compounds needs a source custom synthesis research use only mislabelling Sequence verification for an obscure compound: how it is done Writing it up because I had to work it out twice and would rather nobody else did. Asking about sequence verification directly, because I have…	+104	114	10k	12mo
Sequence verification for an obscure compound: how it is done — what changed since Compounds › Other compounds custom synthesis needs a source mislabelling On the subject in the title: Sequence verification for an obscure compound: how it is done — what changed since Working notes rather than a conclusion. What changes if the standard account of Sequence…	+100	108	1.3k	8mo
When "no data" is the complete and final answer Compounds › Other compounds custom synthesis mislabelling needs a source research use only Solved Asking directly, because I could not find a straight answer: When "no data" is the complete and final answer Asking about the compound itself rather than about a trial of it. I have read the maintained page…	+154	165	6.3k	15mo
Research-use-only status: what it means legally and practically — does this still hold? Compounds › Other compounds custom synthesis mislabelling needs a source research use only Solved Pinned Asking directly, because I could not find a straight answer: Research-use-only status: what it means legally and practically — does this still hold? Asking about Research-use-only status directly, because I…		2	309	9mo

Related topics — sharing the tags custom synthesis, mislabelling, needs a source

Topic	Participants	Replies	Views	Activity
What would change my mind about repair peptides: a specific answer — one year on Compounds › Repair & healing peptides needs a source observational data TB-500 preprint Closed What would change my mind about repair peptides: a specific answer — one year on I have a specific reason for asking rather than idle curiosity, and the context is below. Documentation question rather than a…	+9	13	42k	19mo
About the Payments category Sourcing › Payments payments research use only documentation quality Pinned Wiki Payment mechanics, chargeback reality, and the recurring risks. No payment facilitation of any kind here. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…		4	3.5k	20mo
Follow-up: Why we hide unevidenced fraud accusations and log the hiding Sourcing › Red flags mislabelling disputed moderation underdosing The question in the title: Why we hide unevidenced fraud accusations and log the hiding I will give what I have already checked below so nobody repeats it. Filing a documentation observation rather than a…	+12	16	17k	12mo
TB-500 and thymosin beta-4: the fragment versus the protein — does this still hold? Compounds › Repair & healing peptides TB-500 BPC-157 needs a source Closed TB-500 and thymosin beta-4: the fragment versus the protein — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Two things I would like separated…	+19	23	4.2k	19mo
Follow-up: Reading an interaction checker output critically Practice › Interactions insulin hypoglycaemia delayed gastric emptying needs a source Solved Reading an interaction checker output critically — setting out what I have, and where I think it stops being reliable. A follow-up question about Reading an interaction checker output that I did not know to…	+62	66	13k	2d